亚洲社会药学

本期目录

2025年, 第20卷, 第3期　刊出日期：2025-09-15 上一期   

Select

Research on Coordination Model of Pharmaceutical Supply Chain under Carbon Emission Trading Policy Zhang Minghe, Huang Zhe 2025 (3):  199-211.  摘要 ( 14 )   PDF(6028KB) ( 18 )   Objective To provide effective decision making for the subsidy policies given by the government to pharmaceutical enterprises and the coordination model adopted by pharmaceutical stakeholders under the carbon emission trading policy. Methods The Stackelberg model was used to discuss the optimal profits of each member and the whole supply chain under different decision-making models while considering the technical capacity of emission reduction and cost sharing contract. Based on this, the impact of the combined contract decisionmaking model on the technical efforts of drug manufacturers to reduce carbon emission, the profits of supply chain members and the overall profits of supply chain was investigated. Results and Conclusion Research has found that improving the research and development efforts of emission reduction technologies by pharmaceutical enterprises can increase drug sales and enhance the expected profits of pharmaceutical supply chain members. The members of the secondary pharmaceutical supply chain can achieve the optimal expected profit when reaching cooperation. Besides, when the cost sharing contract and quantity discount contract meet the constraint conditions, the combined contract decision model can perfectly coordinate the pharmaceutical supply chain, enabling supply chain members to achieve Pareto improvement and gradually reach Pareto optimum. 相关文章 | 计量指标

Select

Literature Analysis of Adverse Effects Induced by Sunitinib Lv Mengru, Tian Lijuan 2025 (3):  212-221.  摘要 ( 12 )   PDF(1116KB) ( 11 )   Objective To analyze adverse drug reactions (ADR) caused by sunitinib and provide reference for clinical safety. Methods The case reports of ADR related to sunitinib in six Chinese and English databases from 2006 to 2021 were searched to extract relevant data, and then statistical analysis was performed. Results and Conclusion A total of 147 articles were included, involving 156 cases and 283 adverse events. Adverse reactions occurred at the highest rate after 31 to 180 days of drug administration, and ADR involved organs/systems mainly in blood and lymphatic disorders (17.67%), gastrointestinal disorders (15.55%), and skin and subcutaneous tissue disorders (10.60%). The adverse effects caused by sunitinib involve multiple organs/systems throughout the body. Besides, there are many severe fatal cases. During clinical medication, patients should be monitored regularly, and drugs should be reduced or stopped timely when adverse reactions occur to reduce the risk of clinical medication. 相关文章 | 计量指标

Select

Quantitative Analysis of the Policy of Centralized Drug Procurement Based on PMC Index Model Duan Xiaoxiang, Wang Shuling 2025 (3):  222-235.  摘要 ( 13 )   PDF(6829KB) ( 12 )   Objective To quantitatively analyze the policy of centralized drug procurement centralized drug procurement in order to provide reference for the subsequent policy formulation and improvement. Methods Text mining method was used to process 15 centralized drugs procurement policies issued at the national level during 2015-2022, and a PMC index evaluation model of centralized drug procurement policies was established. Then, 15 centralized drug procurement policies were quantitatively analyzed from the overall and comparative perspective through an evaluation model. Results and Conclusion The average PMC index of 15 centralized drug procurement policies was 6.95, which was acceptable on the whole. Among them, eight were excellent and seven were acceptable. As to the first-order variables, the centralized drugs procurement policy still lacks incentives and constraints. The comparative results show that there are differences in the content and structure of policies, but they are strongly related to each other. Chinese centralized drug procurement policy has been basically formed, which is closely related to medical insurance and medical policies. However, it is still necessary to pay attention to the structure of the policy to ensure the elaboration of the policy content. 相关文章 | 计量指标

Select

Research and Inspiration of Drug Traceability System in the USA Zhang Qi, Tian Lijuan 2025 (3):  236-244.  摘要 ( 6 )   PDF(4650KB) ( 5 )   Objective To draw on the experience of the construction and development of drug traceability system in the USA and to provide reference for improving China’s drug traceability system. Methods Literature research and comparative study were used to sort out the background and development of drug traceability system in the USA, including drug traceability code, drug traceability model, drug traceability platform and the application of blockchain technology. On this basis, some suggestions on the construction of drug traceability system in China were put forward. Results and Conclusion The United States has a perfect system of laws and regulations on drug traceability, which encourages the construction of third-party traceability platforms to avoid the formation of monopolies. Besides, the application of blockchain technology in the construction of drug traceability system is also relatively mature. It is suggested that China strengthen the construction of drug traceability system, give play to the advantages of third-party traceability platforms, and improve the application of blockchain technology in drug traceability. 相关文章 | 计量指标

Select

Construction of Clinical Evaluation Index System of National Generic Drugs Centralized Bidding Procurement Qiu Qingqing, Yan Wei, Xu Dongyan, Fu Shuyong, Jia Zheng, Xing Hua 2025 (3):  245-255.  摘要 ( 7 )   PDF(3645KB) ( 3 )   Objective To establish a scientific, reliable, objective, and effective clinical comprehensive evaluation system for drugs centralized bidding procurement by government, and to conduct reliability and validity test and empirical analysis of the evaluation index system through simulated measurement. Methods Literature research method was used to select comprehensive evaluation indicators for drugs centralized bidding procurement. Then, Dephi method was applied to screen the final evaluation indicators, and the weight of the indicators was determined using analytic hierarchy process. Results and Conclusion The final clinical efficacy evaluation index system for drugs centralized bidding procurement includes 5 primary indicators and 13 secondary indicators. The experts authority coefficient in this study is high, and their opinions relatively coincide. Through the empirical research, the reliability and structural validity of the indicator system is good. This indicator system enriches methods and tools for scientifically evaluating the clinical efficacy of drugs centralized bidding procurement. 相关文章 | 计量指标

Select

Design of the Quality System for Pharmaceutical Commissioned Production under MAH System Yu Chunyan, Chen Yuwen 2025 (3):  256-266.  摘要 ( 15 )   PDF(838KB) ( 10 )   Objective To ensure the quality and safety of drugs in the whole cycle of pharmaceutical commissioned production under the drug marketing authorization holder (MAH) system, and to establish a perfect quality management system for it. Methods Literature review was used to study the factors that influenced the quality management system of pharmaceutical commissioned production because the implementation of MAH system in China was late, and the experience accumulated by pharmaceutical industry was not enough. Results and Conclusion Based on the MAH system, it is of great significance to establish the quality management system for pharmaceutical commissioned production. 相关文章 | 计量指标

Select

Quality Evaluation and Problem Analysis of China’s Pharmacoeconomics on Hypertension Management Liu Xinying, Sun Lihua, Zhu Tianyu, Chen Ping 2025 (3):  267-275.  摘要 ( 6 )   PDF(2671KB) ( 5 )   Objective To systematically evaluate the quality of pharmacoeconomics on hypertension management, and provide reference for promoting the development of pharmacoeconomics in China. Methods Some Chinese databases including CNKI, VIP, Wanfang, as well as international databases such as PubMed and Web of Science were searched to collect studies of economic evaluation on hypertension management in China. The quality of health economic studies (QHES) scale was used to assess the quality of the literature and to analyze the current situation and shortcomings of pharmacoeconomics in the field of hypertension in China. Results and Conclusion A total of 363 articles were included in this study. The quality assessment results showed that the average score of pharmacoeconomics on hypertension management was 42.54 points. The quality of literature published by medical institutions was significantly lower than that published by universities/research institutes (41.25 vs. 54.68, P < 0.05). Among the 363 articles, 3.31% (12 articles) were of high quality (75-100 points), 29.20% (106 articles) were of moderate quality (50-74 points), 66.12% (240 articles) were of low quality (25-49 points), and 1.38% (5 articles) were of extremely low quality (0-24 points). These papers have such problems as unclear research perspectives, single research methods, ambiguous data sources, inappropriate study duration for disease characteristics, and insufficient sensitivity analysis factors. Overall, the quality evaluation of pharmacoeconomics on hypertension management in China is generally low with poor standardization, which should be improved in the future. 相关文章 | 计量指标

Select

Evaluation of Clinical Value of Siltuximab in Castleman Disease Based on Multi-criteria Decision-making Li Jiaxun, Guo Xiaoming, Zhang Fang, Dong Li 2025 (3):  276-288.  摘要 ( 4 )   PDF(2464KB) ( 6 )   Objective To evaluate the clinical value of siltuximab in the treatment of Castleman disease based on multicriteria decision analysis (MCDA) and evidence and value: Impact on decision making (EVIDEM) framework. Methods The evidence matrix for quantitative analysis of MCDA was extracted through literature research, and the weight of each evaluation index was calculated by the maximum differentiation measure in conjoint analysis. Besides, the clinical value of siltuximab in the treatment of Castleman disease was analyzed quantitatively and qualitatively based on the results of expert questionnaire surveys. Results and Conclusion The clinical value score of siltuximab was 0.491, and the weight ratio of “therapeutic benefit” (15.39%), “drug effectiveness” (14.46%) and “drug safety” (11.43%) were the three largest. Among the indexes of “drug effectiveness” “drug safety” “patient reported outcome” “therapeutic benefit” and “non-medical cost”, siltuximab for Castleman disease was considered to be a more valuable treatment option than other first-line therapies. By qualitative analysis, 57% experts believed that siltuximab was a better treatment option. The indexes that contribute the most to the overall clinical value of siltuximab are “ therapeutic benefit” “drug effectiveness” and “quality of evidence”, while the indexes that have a negative impact on the clinical value of siltuximab is “drug treatment cost”. 相关文章 | 计量指标

Select

Research on Biopharmaceutical Innovation in Africa Based on Patent Information Oluka Longinus Obinna, Yuan Hongmei 2025 (3):  289-297.  摘要 ( 11 )   PDF(2244KB) ( 12 )   Objective To explore the current state of biopharmaceutical innovation in Africa by analyzing patent data related to biopharmaceutical products in African countries. Methods Based on patent data, simple descriptive statistical methods were used to analyze the trend of patent applications, the geographical distribution of patents, and the distribution of applicants in the pharmaceutical field in Africa. Besides, Excel software was used to draw charts to visualize statistical information. Results and Conclusion According to the result, a large number of patents has been granted in these countries and the number is steadily rising each year. From the figure below, we can see that the largest number of patents was granted to Morocco in 2014 with a total number of 613 patents followed by Tunisia with 315 patents, the African Intellectual Property Organization (OAPI) with 124 patents, South Africa with 106 and Mozambique with 1 patent based on data availability (IncoPat Global Patent Search Database). It was observed that, as patents were granted, the number of applications filed on this continent increased. The largest number of patents has been recorded by Morocco, Tunisia and South Africa. Patent applications in Morocco increased fast with an average annual growth of 7.3%. The increase in patent applications is due to improved research infrastructure and enhanced research activities, which shows the importance of biopharmaceutical innovation in the continent. 相关文章 | 计量指标

Select

The Current Development of Internet Pharmacy Services in China Zhao Xuanhe, Xiu Yu, Wang Shuling 2025 (3):  298-308.  摘要 ( 7 )   PDF(2093KB) ( 7 )   Objective To study the current situation and corresponding characteristics of internet pharmacy services and summarize their core connotations, and to make some suggestions for their future development based on national policies. Methods The literature of the last 20 years that fully or partially matched the theme of internet pharmacy services in China was studied to summarize the status of research and development of remote pharmacy services by combining the web survey method. Results and Conclusion China’s internet pharmacy services include online consultation, science education, information enquiry, follow-up and intervention, and other functions. The main service providers are medical institutions, Internet enterprises, and online drug sales platforms. Internet pharmacy services can improve patients’ compliance with medication and the convenience of medical treatment, which better play the role of pharmacists. However, they also face problems such as the varying service qualities, the small number of users, the difficulty in popularizing services in remote areas, and the lack of supervision and protection of patients’ rights. 相关文章 | 计量指标